The brain‐penetrant ATM inhibitor, AZD1390, promotes axon regeneration and functional recovery in preclinical models of spinal cord injury

This study demonstrates that AZD1390, an orally bioavailable, brain-penetrant, potent, and highly selective inhibitor of ataxia–telangiectasia mutated (ATM), promotes dramatic recovery after spinal cord injury (SCI). AZD1390 engaged and suppressed its target and promoted dorsal root ganglion neuron (DRGN) neurite outgrowth in vitro and stimulated axon regeneration after SCI in vivo, with the recovery of conductance across the lesion site and led to remarkable improvements in sensory and locomotor function. AZD1390 is currently in clinical development for cancers. 1 The simple oral administration route and good safety profile suggests that AZD1390 is a potential new therapy to promote recovery of function after SCI in patients.

the downstream events of the DNA damage response, such as cell-cycle arrest, repair, and apoptosis. ATM is active in all stages of the cell cycle and regulates DSB repair via non-homologous end-joining and homologous recombination (HR). In contrast, ATR primarily regulates HR and is important for the resolution of replication stress. As HR is restricted to the S2 and G2 phases of the cell cycle, ATM is likely to be the principal regulator of DSB repair in postmitotic neurons. 5,6 We used an adult mouse DRGN culture system with added CNS myelin extracts, containing high titres of Nogo-A, myelin-associated glycoprotein, and chondroitin sulphate proteoglycans 7 to mimic the environment of the injured CNS to test the effects of AZD1390 on DRGN survival and neurite outgrowth. The treatment of DRGN cultures with increasing concentrations of AZD1390 from 1 to 10 nM significantly reduced the levels of ATM activation (phosphorylated ATM [pATM] levels), with 5 nM being the lowest most effective dose ( Figure 1A,B). Suppression of pATM with 5-nM AZD1390 corresponded to a 60%, 88%, and 81% increase in DRGN survival, % DRGN with neurites, and longest neurite length compared to vehicletreated DRGN, respectively ( Figure 1C-E). In comparison, another tool inhibitor of ATM, KU-60019, 8 showed similar levels of DRGN survival, % DRGN with neurites, and the mean longest neurite length as observed with AZD1390 ( Figure 2C-F). These results suggest that the inhibition of ATM in vitro using either AZD1390 or KU-60019 promotes similar levels of significant DRGN survival and disinhibited neurite outgrowth.
After a dorsal column (DC) SCI in mice, 9 only oral delivery of a previously optimized 20-mg/kg dose of AZD1390, once daily, 1   Fibroblast growth factor-2 (FGF2) was used as a positive control. KU-60019 also promoted similar levels of DRGN survival and neurite outgrowth as AZD1390. Scale bars = 50 µm in (F). n = 3 wells/condition, three independent repeats (total n = 9 wells/condition). ***p < .0001, one-way ANOVA with Dunnett's post hoc test delivery of KU-60019 had no effect on ATM levels, even at much higher levels up to 100 mg/kg (Figures 2A,B and S1). However, in separate experiments, intrathecal delivery of 10 µg of KU-60019 after SCI suppressed pATM levels by 81% ( Figure S1), consistent with our previously published report 8 demonstrating that KU-60019 is not available in the CNS after oral delivery but is available after intrathecal injection. Consistent with the suppression of pATM levels in AZD1390-treated animals, cholera toxin B tracing of axons showed that only oral AZD1390, but not KU-60019, promoted DC axon regeneration through the lesion site and into the rostral cord ( Figure 2C,D).
Electrophysiology demonstrated that the normal compound action potential (CAP) trace across the lesion site was ablated after injury ( Figure 3A). Only oral AZD1390 treatment, and not equivalent doses of oral KU-60019, returned a significant CAP trace ( Figure 3A), CAP amplitude ( Figure 3B), and CAP area ( Figure 3C). This return of electrophysiological function in AZD1390-treated animals after SCI, together with the possible remodelling of local circuitry, correlated with significant improvements in sensory ( Figure 3D) and locomotor ( Figure 3E) function, such that AZD1390-treated animals were indistinguishable from sham-treated control animals by 4 weeks after SCI ( Figure 3D,E). As the rat SCI model is considered to be a good translational model that accurately models the human SCI pathophysiology, 9,10 we also showed that oral AZD1390 and not oral KU-60019 (both dosed at 20 mg/kg, once daily) suppressed ATM activation ( Figure 4A,B) and could return a similar significant CAP trace ( Figure 4C), CAP amplitude ( Figure 4D), and CAP area ( Figure 4E) after DC injury in adult rats, correlating with significantly improved sensory ( Figure 4F) and locomotor ( Figure 4G) function. We have previously shown that intrathecal delivery of KU-60019 after DC injury in rats does engage its target and promotes significant electrophysiological, sensory, and locomotor F I G U R E 3 Suppression of phosphorylated ataxia-telangiectasia mutated (pATM) with AZD1390 promotes electrophysiological, sensory, and locomotor function recovery after dorsal column (DC) injury in mice. (A) Representative Spike 2 processed compound action potential (CAP) traces after oral delivery of ataxia-telangiectasia mutated (ATM) inhibitors. The normal CAP trace is ablated after DC injury and significantly restored by oral AZD1390 but not by oral KU-60019 (both dosed at 20 mg/kg, once daily). Dorsal hemisection at the end of the experiments ablated all CAP traces demonstrating the technical success of the experiment. Oral AZD1390 significantly improved (B) CAP amplitudes and (C) CAP areas at 6 weeks after DC injury. Only oral AZD1390 significantly improved (D) tape sensing and removal times and (E) ladder crossing performance (locomotor function) over 6 weeks after DC injury. n = 6 mice/group, two independent experiments (total n = 12 mice/group). ***p = .0001, one-way ANOVA with Dunnett's post hoc test. #p = .00011, linear mixed models; ##p = .00012, generalized linear mixed models improvements, 8 but here, oral delivery of KU-60019 had no effect again suggesting that orally delivered KU-60019 does not reach the CNS.
In conclusion, we show that brain-penetrant, orally bioavailable AZD1390, engaged with its target in the CNS and promoted DRGN survival and neurite outgrowth in vitro and axon regeneration and functional recovery after SCI in both mice and rats in vivo. Therefore, AZD1390 could be a first-in-class reparative drug for the treatment of SCI with a favourable delivery mode.

F I G U R E 4
Suppression of phosphorylated ataxia-telangiectasia mutated (pATM) with AZD1390 also promotes electrophysiological, sensory, and locomotor function recovery after dorsal column (DC) injury in the rat. (A) Western blot and (B) densitometry show that oral AZD1390 (20 mg/kg, once daily) significantly suppresses pATM levels in dorsal root ganglia (DRG) at 4 weeks after DC injury in the rat. Again, KU-60019 (20 mg/kg, once daily) did not alter pATM levels by oral delivery in rats. (C) Representative Spike 2 processed compound action potential (CAP) traces after oral delivery of ataxia-telangiectasia mutated (ATM) inhibitors. The normal CAP trace is ablated after DC injury and significantly restored by oral AZD1390 but not by oral KU-60019 (both dosed at 20 mg/kg, once daily). Dorsal hemisection at the end of the experiments ablated all CAP traces demonstrating the technical success of the experiment. Oral AZD1390 significantly improved (D) CAP amplitudes and (E) CAP areas at 6 weeks after DC injury. Only oral AZD1390 significantly improved (F) tape sensing and removal times and (G) ladder crossing performance (locomotor function) over 6 weeks after DC injury. n = 6 rats/group, two independent experiments (total n = 12 rats/group). ***p = .0001, one-way ANOVA with Dunnett's post hoc test. #p = .00011, linear mixed models; ##p = .00012, generalized linear mixed models A C K N O W L E D G E M E N T S This research was funded by a grant from the Medical Research Council UK (Grant no: MC_PC_15048). We thank the staff in the University of Birmingham's Biomedical Services Unit for technical assistance with all animal experiments. We also thank AstraZeneca (UK) for providing AZD1390 under a material transfer agreement through the AstraZeneca Open Innovations programme.

C O N F L I C T O F I N T E R E S T
ZA and RIT are inventors on a patent related to this work. Zubair Ahmed 1,2 Richard I. Tuxworth 2,3